vs
Side-by-side financial comparison of Acadia Healthcare Company, Inc. (ACHC) and Calumet, Inc. (CLMT). Click either name above to swap in a different company.
Calumet, Inc. is the larger business by last-quarter revenue ($1.0B vs $829.0M, roughly 1.3× Acadia Healthcare Company, Inc.). Acadia Healthcare Company, Inc. runs the higher net margin — 0.5% vs -3.6%, a 4.1% gap on every dollar of revenue.
Acadia Healthcare Company, Inc. is an American provider of for-profit behavioral healthcare services. It operates a network of over 225 facilities across the United States and Puerto Rico.
Calumet, Inc. is a U.S.-headquartered specialty products firm that manufactures and distributes high-value hydrocarbon and specialty chemical products. Its offerings include specialty oils, lubricants, waxes, and renewable fuel solutions, serving industrial, consumer, and transportation segments across North America.
ACHC vs CLMT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $829.0M | $1.0B |
| Net Profit | $4.5M | $-37.3M |
| Gross Margin | — | -0.3% |
| Operating Margin | — | -6.2% |
| Net Margin | 0.5% | -3.6% |
| Revenue YoY | 7.5% | — |
| Net Profit YoY | -50.8% | — |
| EPS (diluted) | $0.05 | $-0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $829.0M | — | ||
| Q4 25 | $821.5M | $1.0B | ||
| Q3 25 | $851.6M | $1.1B | ||
| Q2 25 | $869.2M | $1.0B | ||
| Q1 25 | $770.5M | $993.9M | ||
| Q4 24 | $774.2M | — | ||
| Q3 24 | $815.6M | $1.1B | ||
| Q2 24 | $796.0M | $1.1B |
| Q1 26 | $4.5M | — | ||
| Q4 25 | $-1.2B | $-37.3M | ||
| Q3 25 | $36.2M | $313.4M | ||
| Q2 25 | $30.1M | $-147.9M | ||
| Q1 25 | $8.4M | $-162.0M | ||
| Q4 24 | $32.6M | — | ||
| Q3 24 | $68.1M | $-100.6M | ||
| Q2 24 | $78.5M | $-39.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | -0.3% | ||
| Q3 25 | — | 34.7% | ||
| Q2 25 | — | -4.2% | ||
| Q1 25 | — | -8.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.4% | ||
| Q2 24 | — | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | -142.4% | -6.2% | ||
| Q3 25 | 4.7% | 30.0% | ||
| Q2 25 | 5.8% | -9.8% | ||
| Q1 25 | 1.7% | -4.9% | ||
| Q4 24 | 4.9% | — | ||
| Q3 24 | 12.1% | -5.2% | ||
| Q2 24 | 13.4% | 0.5% |
| Q1 26 | 0.5% | — | ||
| Q4 25 | -143.3% | -3.6% | ||
| Q3 25 | 4.3% | 29.1% | ||
| Q2 25 | 3.5% | -14.4% | ||
| Q1 25 | 1.1% | -16.3% | ||
| Q4 24 | 4.2% | — | ||
| Q3 24 | 8.4% | -9.1% | ||
| Q2 24 | 9.9% | -3.4% |
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-12.98 | $-0.43 | ||
| Q3 25 | $0.40 | $3.61 | ||
| Q2 25 | $0.33 | $-1.70 | ||
| Q1 25 | $0.09 | $-1.87 | ||
| Q4 24 | $0.36 | — | ||
| Q3 24 | $0.74 | $-1.18 | ||
| Q2 24 | $0.85 | $-0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $158.5M | $125.1M |
| Total DebtLower is stronger | $2.5B | $2.1B |
| Stockholders' EquityBook value | $2.0B | $-732.7M |
| Total Assets | $5.5B | $2.7B |
| Debt / EquityLower = less leverage | 1.29× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $158.5M | — | ||
| Q4 25 | $133.2M | $125.1M | ||
| Q3 25 | $118.7M | $94.6M | ||
| Q2 25 | $131.4M | $110.6M | ||
| Q1 25 | $91.2M | $123.4M | ||
| Q4 24 | $76.3M | — | ||
| Q3 24 | $82.1M | $34.6M | ||
| Q2 24 | $77.2M | $7.0M |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | $2.1B | ||
| Q3 25 | $2.3B | $2.1B | ||
| Q2 25 | $2.3B | $2.1B | ||
| Q1 25 | $2.2B | $2.3B | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $1.9B | $1.7B | ||
| Q2 24 | $1.8B | — |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $1.9B | $-732.7M | ||
| Q3 25 | $3.1B | $-695.3M | ||
| Q2 25 | $3.1B | $-1.0B | ||
| Q1 25 | $3.0B | $-862.3M | ||
| Q4 24 | $3.1B | — | ||
| Q3 24 | $3.0B | $-672.2M | ||
| Q2 24 | $3.0B | $-566.4M |
| Q1 26 | $5.5B | — | ||
| Q4 25 | $5.5B | $2.7B | ||
| Q3 25 | $6.4B | $2.7B | ||
| Q2 25 | $6.3B | $2.8B | ||
| Q1 25 | $6.1B | $2.8B | ||
| Q4 24 | $6.0B | — | ||
| Q3 24 | $5.9B | $2.6B | ||
| Q2 24 | $5.7B | $100 |
| Q1 26 | 1.29× | — | ||
| Q4 25 | 1.28× | — | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.72× | — | ||
| Q4 24 | 0.64× | — | ||
| Q3 24 | 0.62× | — | ||
| Q2 24 | 0.62× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $61.5M | $116.5M |
| Free Cash FlowOCF − Capex | — | $103.8M |
| FCF MarginFCF / Revenue | — | 10.0% |
| Capex IntensityCapex / Revenue | — | 1.2% |
| Cash ConversionOCF / Net Profit | 13.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $56.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $61.5M | — | ||
| Q4 25 | $-86.3M | $116.5M | ||
| Q3 25 | $73.2M | $23.5M | ||
| Q2 25 | $133.5M | $-1.8M | ||
| Q1 25 | $11.5M | $-29.3M | ||
| Q4 24 | $116.7M | — | ||
| Q3 24 | $163.1M | $-15.5M | ||
| Q2 24 | $171.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-179.5M | $103.8M | ||
| Q3 25 | $-63.0M | $15.1M | ||
| Q2 25 | $-34.2M | $-15.4M | ||
| Q1 25 | $-163.2M | $-46.9M | ||
| Q4 24 | $-86.8M | — | ||
| Q3 24 | $-27.1M | $-32.2M | ||
| Q2 24 | $16.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | -21.8% | 10.0% | ||
| Q3 25 | -7.4% | 1.4% | ||
| Q2 25 | -3.9% | -1.5% | ||
| Q1 25 | -21.2% | -4.7% | ||
| Q4 24 | -11.2% | — | ||
| Q3 24 | -3.3% | -2.9% | ||
| Q2 24 | 2.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.3% | 1.2% | ||
| Q3 25 | 16.0% | 0.8% | ||
| Q2 25 | 19.3% | 1.3% | ||
| Q1 25 | 22.7% | 1.8% | ||
| Q4 24 | 26.3% | — | ||
| Q3 24 | 23.3% | 1.5% | ||
| Q2 24 | 19.4% | 2.2% |
| Q1 26 | 13.78× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.02× | 0.07× | ||
| Q2 25 | 4.43× | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 2.39× | — | ||
| Q2 24 | 2.18× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACHC
| Acute Inpatient Psychiatric Facilities | $471.0M | 57% |
| Other | $140.0M | 17% |
| Specialty Treatment Facilities | $128.0M | 15% |
| Residential Treatment Facilities | $90.0M | 11% |
CLMT
| Specialty Products And Solutions | $675.9M | 65% |
| Montana Renewables | $294.2M | 28% |
| Performance Brands | $68.5M | 7% |
